AllergyTalk

By allergytalkScience Medicine Health & Fitness

AllergyTalk episodes

October 29, 2019 Episode 6: Telemedicine in allergy/immunology
We are excited to present a special episode of Allergytalk! Dr. Jennifer Shih, MD joins the podcast to discuss the use of telemedicine in allergy/immunology!

Please give us feedback, corrections, and suggestions!
If you have a topic you’d like to cover in a future podcast, let us know at [email protected]
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee was on an advisory board for Teva.
Dr. Kalangara has received consulting fees from AstraZeneca.
Dr. Shih was on advisory board for Teva and Tekeda.
30 min
October 02, 2019 •Episode 5: Risk Factors for Venom Allergy, Triggers for Adult-onset Asthma and Associations Between Pollution and ED Visits
This is part 2 of our summaries from the July-August 2019 issue of Allergy Watch:
Investigation of the factors that determine the severity of allergic reactions to Hymenoptera venoms
https://www.ncbi.nlm.nih.gov/pubmed/30819281
New-Onset Asthma in Adults: What Does the Trigger History Tell Us?
https://www.ncbi.nlm.nih.gov/pubmed/30240884
Age-Specific Associations of Ozone and Fine Particulate Matter with Respiratory Emergency Department Visits in the United States
https://www.ncbi.nlm.nih.gov/pubmed/30277796
Please give us feedback, corrections, and suggestions!
Email feedback to: [email protected]
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee was on an advisory board for Teva.
Dr. Kalangara has received consulting fees from AstraZeneca.
Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.
30 min
October 02, 2019 Episode 4: Dupliumab for Nasal Polyps, Cockroach Immunotherapy and Immediate Food Allergy in EoE
For today’s episode we will be reviewing three articles from the July-August 2019 issue of Allergy Watch:
Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis
https://www.ncbi.nlm.nih.gov/pubmed/30488542
Allergen content in German cockroach extracts and sensitization profiles to a new expanded set of cockroach allergens determine in vitro extract potency for IgE reactivity
https://www.ncbi.nlm.nih.gov/pubmed/30170124
New IgE immediate hypersensitivity reactions on reintroduction of food restricted for treatment of eosinophilic esophagitis
https://www.ncbi.nlm.nih.gov/pubmed/30684739
Please give us feedback, corrections, and suggestions!
Email feedback to: [email protected]
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee was on an advisory board for Teva.
Dr. Kalangara has received consulting fees from AstraZeneca.
Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.
37 min
July 23, 2019Episode 3: Food Allergy & Eczema
For today’s episode we will be reviewing three articles about food allergy and eczema from the May-June 2019 issue of Allergy Watch:
The Basophil Activation Test reduces the need for a food challenge test in children suspected of IgE-mediated cow's milk allergy.
https://www.ncbi.nlm.nih.gov/pubmed/30408255
Oral food challenge failures among foods restricted because of atopic dermatitis.
https://www.ncbi.nlm.nih.gov/pubmed/30326323
The nonlesional skin surface distinguishes atopic dermatitis with food allergy as a unique endotype.
https://www.ncbi.nlm.nih.gov/pubmed/30787169
Please give us feedback, corrections, and suggestions!
Email feedback to: [email protected]
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee was on an advisory board for Teva.
Dr. Kalangara has received consulting fees from Astra Zenica.
Dr. Fineman
Speaker: AstraZenca, Boehringer Ingelheim, Shire
Research: Aimmune, DBV, Shire, Regeneron.
29 min
July 23, 2019Episode 2: Asthma
For today’s episode we will be reviewing three articles about asthma from the May-June 2019 issue of Allergy Watch:
Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
https://www.ncbi.nlm.nih.gov/pubmed/30217529
Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison.
https://www.ncbi.nlm.nih.gov/pubmed/30205189
Indirect Treatment Comparisons and Biologics
https://www.ncbi.nlm.nih.gov/pubmed/30612667
Endotypes of severe allergic asthma patients who clinically benefit from anti?IgE therapy
https://www.ncbi.nlm.nih.gov/pubmed/30107059/
Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma
https://www.ncbi.nlm.nih.gov/pubmed/29301922
Please give us feedback, corrections, and suggestions!

Email feedback to: [email protected]

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Dr. Lee was on an advisory board for Teva.

Dr. Kalangara has received consulting fees from Astra Zenica.

Dr. Fineman
Speaker: AstraZenca, Boehringer Ingelheim, Shire
Research: Aimmune, DBV, Shire, Regeneron.
38 min
May 15, 2019 Episode 1
With guest Stanley Fineman, MD, MBA, FACAAI, editor-in-chief of AllergyWatch.
48 min

About AllergyTalk

From the publisher's feed

AllergyTalk delivers the latest insights and evidence shaping allergy and immunology. In each bimonthly episode, leading experts break down the most impactful research and real-world takeaways from…